Fig. 2.

Representative targets of SIRT1 in hematologic malignancies

SIRT1 enhances target activity (labeled in brown), promoting hematologic malignancies; SIRT1 decreases target activity (labeled in grey), promoting hematologic malignancies; SIRT1 enhances target activity (labeled in blue), suppressing hematologic malignancies. AML, acute myeloid leukemia; CML, chronic myelogenous leukemia; LSC, leukemia stem cell; MLL-r, mixed-lineage leukemia-rearranged; MDS, myelodysplastic syndrome; HSPC, hematopoietic stem/progenitor cell; ALL, acute lymphoblastic leukemia; cHL, classical Hodgkin lymphoma; DLBCL, diffuse large B-cell lymphoma; PEL, primary effusion lymphoma